



---

# OPTO CIRCUITS (INDIA) LIMITED.

---

16<sup>th</sup> January 2015

Bombay Stock Exchange Limited.,  
Listing Department,  
P J Towers, Dalal Street,  
MUMBAI – 400 001.

National Stock Exchange of India Limited.,  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E),  
MUMBAI – 400 051.

Dear Sir,

Subject: Press Release.

We would like to inform you that Eurocor GmbH a group company of Opto Circuits (India) Limited has received **CE Mark (Communauté Européenne)** approval for E-Magic Plus<sup>TM</sup> Sirolimus Eluting Coronary Stent System,

We are enclosing herewith the press release regarding this.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully.

**for OPTO CIRCUITS (INDIA) LTD.,**

Authorised Signatory

CIN NO: L85110KA1992PLC013223



# OPTO CIRCUITS (INDIA) LIMITED.

## PRESS RELEASE

Eurocor GmbH, a group company of Opto Circuits (India) Ltd. (Bloomberg: OPTC IN; Reuters: OPTO. NS; NSE: OPTOCIRCUI; BSE: 532391), is pleased to announce that the E-Magic Plus™ Sirolimus Eluting Coronary Stent System, has received CE (Conformité Européenne) Mark approval.

E-Magic Plus™ is providing the latest technology in combining ultra-thin strut of a CoCr stent, with an optimal Sirolimus coating. Fully biodegradable polymer is minimizing delayed healing and late adverse events.

Mr. Vinod Ramnani CMD of Opto Circuits (India) Limited commented, " The CE mark approval of E-Magic Plus™, represents a key milestone for Eurocor GmbH. We are now back in the largest cardiovascular product range, the DES. Thanks to its innovative technology, we'll be able to further expand treatment options for patients with introduction of E-Magic Plus – highly differentiated DES with Sirolimus Coating and biodegradable polymer.

E-Magic Plus™ received registration approval in India last year and has been available for sale for few months already. More than 3000 implants have been completed so far, and preliminary outcomes are in line with expectations, with no MACE nor re-intervention.

As stated by Prof P. Chandra (The Medicity, India), "E-Magic Plus™ has the lowest strut thickness, which is key to reduce risks of clinical and angiographic restenosis (according to ISAR STEREO II). I'm very happy with its acute results as well as post therapy results"

With this CE Mark approval, Eurocor GmbH is preparing to make the E-Magic Plus™ commercially available in Europe and other markets where CE Mark approval can expedite the registration process.

### Media Contact

Eurocor GmbH

Myriam Luu

Phone: +49 (0) 228 201 500

Email: [pressoffice@eurocor.de](mailto:pressoffice@eurocor.de)

### The Company:

Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.

Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.

For more information, please visit [eurocor.de](http://eurocor.de) and [optocircuits.com](http://optocircuits.com).

CIN NO: L85110KA1992PLC013223

Plot No. 83, Electronics City, Bangalore - 560 100.  
Phone : +91-80-28521040-41-42 Fax : +91-80-28521094  
E-mail : [oci@optoindia.com](mailto:oci@optoindia.com), [info@optoindia.com](mailto:info@optoindia.com) Web: [www.optocircuits.com](http://www.optocircuits.com)

